NR4A2 and cancer: Structure-activity studies have identified a series of 3,5-disubstitutedphenyl CDIM (DIM-3,5) analogs that inhibit mammary tumor growth in athymic nude mice bearing MDA-MB-231 cells at doses <1 mg/kg/day [18] and the highly potent DIM-3,5 compounds have recently been identified as unique dual NR4A1/2 ligands that bind both NR4A1 and NR4A2, and act as inverse agonists in cancer cells [19].